Disclosed are compounds, for example, compounds of formula I, ##STR00001##
wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Disclosed are compounds, for example, compounds of formula I, ##STR00001##
wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

The present invention relates to a novel N-acylurea derivative and the use thereof for the prevention or treatment of cardiovascular disease, and more particularly to a novel N-acylurea derivative, a pharmaceutical composition for prevention or treatment of cardiovascular disease, which contains the N-acylurea derivative as an active ingredient, and a method of preparing the N-acylurea derivative. The N-acylurea derivative according to the present invention can inhibit platelet aggregation by inhibiting the activity of talin in the intracellular matrix, and thus can be useful for the prevention or treatment of cardiovascular disease.

The present invention relates to a novel N-acylurea derivative and the use thereof for the prevention or treatment of cardiovascular disease, and more particularly to a novel N-acylurea derivative, a pharmaceutical composition for prevention or treatment of cardiovascular disease, which contains the N-acylurea derivative as an active ingredient, and a method of preparing the N-acylurea derivative. The N-acylurea derivative according to the present invention can inhibit platelet aggregation by inhibiting the activity of talin in the intracellular matrix, and thus can be useful for the prevention or treatment of cardiovascular disease.

Described herein is a compound of formula (I)

##STR00001##

in the form of any one of its stereoisomers or as a mixture thereof, and wherein R.sup.1 represents a hydrogen atom, a C.sub.1-3 alkyl group or C.sub.2-3 alkenyl group; X represents an oxygen atom when R.sup.2 represents a C.sub.1-4 alkyl group or C.sub.2-4 alkenyl group or X represents a CH2-O group when R.sup.2 represents a C.sub.2-4 alkenyl group or a MeC═O group. The use as a perfuming ingredient of this compound and this compound as part of a perfuming composition or of a perfuming consumer product are also described.

The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

The present invention belongs to the field of organic chemical synthesis, and provides a method for simultaneously preparing 2-ethoxyphenol and 1,3-benzodioxol-2-one. In the present invention, catechol and diethyl carbonate are subjected to a transesterification reaction under the action of a catalyst to obtain 2-ethoxyphenol and 1,3-benzodioxol-2-one. In the present invention, the combined selectivity of 2-ethoxyphenol and 1,3-benzodioxol-2-one can reach 97%. The method has the advantages of high conversion rate, high selectivity, high economic benefit, environmental friendliness and the like.

The present invention belongs to the field of organic chemical synthesis, and provides a method for simultaneously preparing 2-ethoxyphenol and 1,3-benzodioxol-2-one. In the present invention, catechol and diethyl carbonate are subjected to a transesterification reaction under the action of a catalyst to obtain 2-ethoxyphenol and 1,3-benzodioxol-2-one. In the present invention, the combined selectivity of 2-ethoxyphenol and 1,3-benzodioxol-2-one can reach 97%. The method has the advantages of high conversion rate, high selectivity, high economic benefit, environmental friendliness and the like.

Disclosed are compounds, for example, compounds of formula I, ##STR00001##
wherein R, R.sub.0, R.sub.1-R.sub.8, n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.